Hutchmed (china) Share Discussion Threads

[nerdofsteel] 01/8/2021 20:22

explain the relevance to Hutchmed please, Thank You

[lauders] 31/7/2021 04:21

Nice short interview here by CH:



Innovative drugs are safe(r) from Chinese regulation and "interference" than generic.

[lauders] 31/7/2021 02:11

So much for global markets!

More like "So much for efficient markets!" LOL

Will be nice to see HCM over 700p one of these coming days.

[dbadvn] 29/7/2021 21:25

That’s a very sad sjack.

Usd close at near as 41usd, hk at almost 50usd. More than 20% difference.

So much for global markets!

[steeplejack] 29/7/2021 20:45

You’re not going to have your top marketmaker mechanics making a book in a relatively lowly traded AIM stock like Hutchmed.The name of the game is to keep a low profile,monkey with a wide spread and wait to sneak under the umbrella afforded by the Nasdaq market.Marketmakers are invariably little more than day traders,happy to trot off to the bar of an evening with a square book .Their advantage is being able to accurately gauge the sentiment surrounding a stock as a result of handling,observing order flow.A weather vane of sorts.This doesn’t make them clever so much as relatively privileged due to delayed order reporting etc.They have the easy access and cost advantages of being able to exploit potential arbitrage opportunities but at the end of the day,they’d rather make a few quid crossing a million Astra Zeneca for a tenth of a penny.

[fionascott1234] 29/7/2021 15:26

As always, a license to print money!

[dbadvn] 29/7/2021 15:24

Sportii,

can't be that clever if they allow a 17% arbitrage opportunity to pass them by...

[dbadvn] 29/7/2021 15:18

right now (1515 BST) HK closing price is USD 49.95 equivalent and Nasdaq price is USD 41.33,

17% difference.

Amazing !

[sportii] 29/7/2021 15:12

ADRs improve once the aim market closes. This phenomenon has become a norm! MMs are a clever bunch.

[dbadvn] 29/7/2021 15:11

Chester, agree.

For nearly 5 hours there was an almost 15% gap in the Hk and the Us price - surely someone with the right market access could arbitrage that successfully. Need someone with real trading knowledge but suspect the ADR / DI structure of the public holdings mean that their is a structural barrier to buying in the US and selling in HK

If the gap persists and gets wider I assume the company will have to comment and make some move to close it although not clear how they can.

[chester9] 29/7/2021 14:52

The market is very strange London 9% up to 2:30 then NASDAQ opens and it loses 6% in 5 minutes. Hong Kong has it at over £7?Is this supply and demand on shares in HK as differential is mad. Does this make sense to someone?

[steeplejack] 29/7/2021 09:04

Closing around 76HK.Our AIM marketmakers continue to pay homage to the nasdaq quote.The AIM marketmakers could well be short.There's a real reluctance to follow the HK price hike and that sometimes indicates a desire to hose down enthusiasm until they get square ie a bit like Goldmans refusing to correctly price subprime in 2008 until they themselves were short.Speculation on my part.I appreciate the AIM market affording buying opportunities.

[steeplejack] 29/7/2021 07:45

It’ll be interesting to see how our marketmaker trojans on the AIM market open up this morning.(On Monday,they marked the stock down to 535p).The US closed last night at £6 equivalent but with the HK quote now over 76HK,up over 15%,thats around 706p equivalent.I suppose they’ll split the difference and open up around 650p.

[nerdofsteel] 29/7/2021 07:04

P/S and other metrics finally on a par with Innovent and Beigene. The Company said clearly yesterday they will be a large global Biopharma by 2025. Revenues will be far in excess of $1bn by then and they should be cashflow positive too.

[steeplejack] 29/7/2021 06:46

Stock currently back over 73HK +10%,673p equivalent.

[mcmather] 28/7/2021 17:11

Both the webcast and, especially, the interims came after HK closed . 650p tomorrow??

[nerdofsteel] 28/7/2021 12:38

Brilliant set of results - great example of progress

· ELUNATE® (fruquintinib in China) in-market sales increased 186% to $40.1 million (H1-20: $14.0m

$20bn+ mcap by 2025

[dbadvn] 28/7/2021 12:16

Almost 10% difference between hk close and uk price.

Some smart guy with the right market access is going to clean up , even with exchange rate differences surely has to be a clear 5% no risk gain?

[lauders] 28/7/2021 12:02

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force

Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA®

U.S. and E.U. applications for surufatinib both accepted

Raised $615m2 gross proceeds from additional listing on HKEX3

Company to Host Interim Results Call & Webcast Today at 8 p.m. HKT / 1 p.m. BST / 8 a.m. EDT

[lauders] 28/7/2021 05:33

5% up in HK so far on this news:

HUTCHMED (China) Limited (“HUTCHMED”) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq: AZN) have initiated a Phase II study of ORPATHYS® (savolitinib), an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer (“GC”) or adenocarcinoma of the gastroesophageal junction (“GEJ”). The first patient was dosed on July 27, 2021.

[nerdofsteel] 26/7/2021 16:07

I've done it before for the AIM and NASDAQ but the Broker currency charges make it almost impossible to get a decent return

[dbadvn] 26/7/2021 13:34

Surely there must be a smart trader somewhere who can arbitrage an almost 10% difference between HK and UK Aim?